array:19 [
  "pii" => "X0211699504029465"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:71-2"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2447
    "formatos" => array:3 [
      "EPUB" => 252
      "HTML" => 1771
      "PDF" => 424
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029457"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:73"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4236
      "formatos" => array:3 [
        "EPUB" => 261
        "HTML" => 3252
        "PDF" => 723
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Marcadores inflamatorios y enfermedad cardiovascular. Efecto del tratamiento hipolipemiante"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "73"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. CACHOFEIRO , V. LAHERA , P. LOPEZ JARAMILLO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. CACHOFEIRO , V. LAHERA , P. LOPEZ JARAMILLO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029457?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029457/v0_201502091335/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029473"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:69-70"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 8119
      "formatos" => array:3 [
        "EPUB" => 277
        "HTML" => 6928
        "PDF" => 914
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Pros y contras de la inhibición del sistema renina angiotensina"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "69"
          "paginaFinal" => "70"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. L. RODICIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. L. RODICIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029473?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029473/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Disfunción renal como factor de riesgo cardiovascular"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "71"
        "paginaFinal" => "72"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "E. RITZ"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "E. RITZ"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Disfunción renal como factor de riesgo cardiovascular E. Ritz Universidad de Heidelberg. Alemania. Following the seminal observation of Lindner and colleagues1 on the excessive cardiovascular mortality in patients with end stage renal disease on renal replacement therapy, this observation has been repeatedly confirmed. It is currently known that in patients on renal replacement therapy the relative risk of dying from cardiac causes is higher by a factor of 10-100, depending on age2. It has only recently been recognised that even minor renal dysfunction, as reflected by an increase in urinary albumin excretion and/or a decrease in glomerular filtration rate, is an independent cardiovascular risk factor3 which should be added to the known factors contributing to the Framingham risk score. Satopinto3 recently reported on an impressively large prospective multicentre observational study covering 11,774 patients in 14 countries hospitalised for acute coronary syndromes. It is commonly agreed upon that the serum creatinine concentration is a non-reliable estimate of glomerular filtration rate. The sensitivity of the estimate can be increased with the so called Cockroft Gault formula which gives an estimate of creatinine clearance. Santopinto and collaborators found that the in-hospital mortality in patients with moderate renal dysfunction (creatinine clearance 30-60 ml/min) is higher by a factor of two (adjusted relative risk (RR) 2.01), while it was higher by a factor of almost four in patients with severe renal dysfunction (odds ratio 3.71). Confirming previous observations 4,5 they also noted that in-hospital medication (interestingly enough not medication taken before admission) was suboptimal, with less intensive use of antiplatelet agents, angiotensin converting enzyme (ACE) inhibitors, and ß blockers --presumably because of a perceived greater risk. That the risk is definitely greater is illustrated in this study by the observation of a higher rate of bleeding, presumably explained by the known platelet dysfunction in renal failure. Both Shlipak and colleagues4 and Wright and associates5 had noted that patients with renal dysfunction had received less diagnostic and therapeutic interventions, such as coronary angiography, coronary angioplasty or coronary bypass graft surgery, again because of an assumed (and real) higher risk of complications --for example, bleeding, radiocontrast renal failure, etc. The documentation of such enormous excess mortality justifies future efforts to provide a detailed and reliable quantitative risk benefit estimate --for example, for the administration of radiocontrast, for administration of antiplatelet agents, etcétera. Nevertheless it remains difficult to understand why physicians hesitate to administer ACE inhibitors or ß blockers to these patients. ADVERSE EFFECT ON SURVIVAL The highly welcome information from the present GRACE (global registry of acute coronary events) study is in perfect agreement with other observations that mild to moderate renal dysfunction has an adverse effect on survival in the general population6,7 in hypertensive individuals examined in the HOT study8, in the high cardiovascular risk population of the HOPE study9, and in patients with congestive heart failure10. While the epidemiological relationship appears now certain beyond any reasonable doubt, the underlying pathophysiological mechanisms have certainly not yet been sufficiently clarified. Nevertheless, recent studies have provided several hints pointing to an increased risk of accelerated atherosclerosis with minor renal dysfunction --for example, uninephrectomy in the apo-E knock out mouse11, increased concentrations of the nitric oxide (NO) synthase inhibitor ADMA in renal patients even when inulin clearance is still within the normal range11, early increase of blood pressure and left ventricular remodelling with evidence of impaired left ventricular diastolic function in renal patients with normal inulin clearance12, insulin resistance with minor renal dysfunction13,14, and sympathetic overactivity in renal patients even with normal glomerular filtration, as documented by microneurographic measurements of action potentials in the sural nerve by Klein and colleagues15. Atherogenesis, NO inhibition, increase in blood pressure and cardiac dysfunction, insulin resistance, and sympathetic overac71 E. RITZ tivity undoubtedly provide an unhealthy mix, but which of the factors is (are) truly culpable (and susceptible to intervention) remains to be shown. RENAL DYSFUNCTION: THE CINDERELLA OF CARDIOVASCULAR RISK There is no doubt, however, that renal dysfunction has remained the Cinderella of the cardiovascular risk profile. There are recent efforts to give renal dysfunction the status of a major cardiac risk factor, similar to diabetes mellitus, where Haffner and colleagues16 had shown that mortality in diabetics without a history of cardiac events was equal to that in nondiabetic patients surviving a myocardial infarction. As a result, in diabetic patients cardiovascular prophylaxis, including administration of ACE inhibitors (independent of blood pressure) and of statins (independent of low density lipoprotein cholesterol values) has been advocated. It will have to be seen whether renal dysfunction will be given a similar status. Nevertheless, in my opinion, because of the excessive cardiac risk, treating a patient with renal dysfunction should no longer be regarded as primary, but rather as secondary prevention. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. REFERENCES 1. Lindner A, Charra B, Sherrard DJ y cols.: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974. 2. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 160615, 1999. 3. Santopinto JJ, Fox KAA, Goldberg RJ y cols.: Creatinine clearance and adverse hospital outcomes in patients with acute 14. 15. 16. coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 89: 1003-8, 2003. Shlipak MG, Heidenreich PA, Noguchi H y cols.: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-62, 2002. Wright RS, Reeder GS, Herzog CA y cols.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137: 563-70, 2002. Henry RM, Kostense PJ, Bos G y cols.: Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 62: 1402-7, 2002. Muntner P, He J, Hamm L y cols.: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-53, 2002. Ruilope LM, Salvetti A, Jamerson K y cols.: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12: 218-25, 2001. Mann JF, Gerstein HC, Pogue J y cols.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-36, 2001. Hillege HL, Girbes AR, de Kam PJ y cols.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-10, 2000. Kielstein JT, Boger RH, Bode-Boger SM y cols.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-6, 2002. Stefanski A, Schmidt KG, Waldherr R y cols.: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50: 1321-6, 1996. Fliser D, Pacini G, Engelleiter R y cols.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343-7, 1998. Chen J, Muntner P, Hamm LL y cols.: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469-77, 2003. Klein IH, Ligtenberg G, Oey PL y cols.: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-33, 2001. Haffner SM, Lehto S, Ronnemaa T y cols.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-34, 1998. 72 "
    "pdfFichero" => "P7-E232-S132-A2999.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029465/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029465/v0_201502091335/en/P7-E232-S132-A2999.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029465?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Disfunción renal como factor de riesgo cardiovascular
E. RITZ
Leído
5393
Veces
se ha leído el artículo
1912
Total PDF
3481
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699504029465"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:71-2"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2447
    "formatos" => array:3 [
      "EPUB" => 252
      "HTML" => 1771
      "PDF" => 424
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029457"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:73"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4236
      "formatos" => array:3 [
        "EPUB" => 261
        "HTML" => 3252
        "PDF" => 723
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Marcadores inflamatorios y enfermedad cardiovascular. Efecto del tratamiento hipolipemiante"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "73"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. CACHOFEIRO , V. LAHERA , P. LOPEZ JARAMILLO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. CACHOFEIRO , V. LAHERA , P. LOPEZ JARAMILLO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029457?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029457/v0_201502091335/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029473"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:69-70"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 8119
      "formatos" => array:3 [
        "EPUB" => 277
        "HTML" => 6928
        "PDF" => 914
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Pros y contras de la inhibición del sistema renina angiotensina"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "69"
          "paginaFinal" => "70"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. L. RODICIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. L. RODICIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029473?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029473/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Disfunción renal como factor de riesgo cardiovascular"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "71"
        "paginaFinal" => "72"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "E. RITZ"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "E. RITZ"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Disfunción renal como factor de riesgo cardiovascular E. Ritz Universidad de Heidelberg. Alemania. Following the seminal observation of Lindner and colleagues1 on the excessive cardiovascular mortality in patients with end stage renal disease on renal replacement therapy, this observation has been repeatedly confirmed. It is currently known that in patients on renal replacement therapy the relative risk of dying from cardiac causes is higher by a factor of 10-100, depending on age2. It has only recently been recognised that even minor renal dysfunction, as reflected by an increase in urinary albumin excretion and/or a decrease in glomerular filtration rate, is an independent cardiovascular risk factor3 which should be added to the known factors contributing to the Framingham risk score. Satopinto3 recently reported on an impressively large prospective multicentre observational study covering 11,774 patients in 14 countries hospitalised for acute coronary syndromes. It is commonly agreed upon that the serum creatinine concentration is a non-reliable estimate of glomerular filtration rate. The sensitivity of the estimate can be increased with the so called Cockroft Gault formula which gives an estimate of creatinine clearance. Santopinto and collaborators found that the in-hospital mortality in patients with moderate renal dysfunction (creatinine clearance 30-60 ml/min) is higher by a factor of two (adjusted relative risk (RR) 2.01), while it was higher by a factor of almost four in patients with severe renal dysfunction (odds ratio 3.71). Confirming previous observations 4,5 they also noted that in-hospital medication (interestingly enough not medication taken before admission) was suboptimal, with less intensive use of antiplatelet agents, angiotensin converting enzyme (ACE) inhibitors, and ß blockers --presumably because of a perceived greater risk. That the risk is definitely greater is illustrated in this study by the observation of a higher rate of bleeding, presumably explained by the known platelet dysfunction in renal failure. Both Shlipak and colleagues4 and Wright and associates5 had noted that patients with renal dysfunction had received less diagnostic and therapeutic interventions, such as coronary angiography, coronary angioplasty or coronary bypass graft surgery, again because of an assumed (and real) higher risk of complications --for example, bleeding, radiocontrast renal failure, etc. The documentation of such enormous excess mortality justifies future efforts to provide a detailed and reliable quantitative risk benefit estimate --for example, for the administration of radiocontrast, for administration of antiplatelet agents, etcétera. Nevertheless it remains difficult to understand why physicians hesitate to administer ACE inhibitors or ß blockers to these patients. ADVERSE EFFECT ON SURVIVAL The highly welcome information from the present GRACE (global registry of acute coronary events) study is in perfect agreement with other observations that mild to moderate renal dysfunction has an adverse effect on survival in the general population6,7 in hypertensive individuals examined in the HOT study8, in the high cardiovascular risk population of the HOPE study9, and in patients with congestive heart failure10. While the epidemiological relationship appears now certain beyond any reasonable doubt, the underlying pathophysiological mechanisms have certainly not yet been sufficiently clarified. Nevertheless, recent studies have provided several hints pointing to an increased risk of accelerated atherosclerosis with minor renal dysfunction --for example, uninephrectomy in the apo-E knock out mouse11, increased concentrations of the nitric oxide (NO) synthase inhibitor ADMA in renal patients even when inulin clearance is still within the normal range11, early increase of blood pressure and left ventricular remodelling with evidence of impaired left ventricular diastolic function in renal patients with normal inulin clearance12, insulin resistance with minor renal dysfunction13,14, and sympathetic overactivity in renal patients even with normal glomerular filtration, as documented by microneurographic measurements of action potentials in the sural nerve by Klein and colleagues15. Atherogenesis, NO inhibition, increase in blood pressure and cardiac dysfunction, insulin resistance, and sympathetic overac71 E. RITZ tivity undoubtedly provide an unhealthy mix, but which of the factors is (are) truly culpable (and susceptible to intervention) remains to be shown. RENAL DYSFUNCTION: THE CINDERELLA OF CARDIOVASCULAR RISK There is no doubt, however, that renal dysfunction has remained the Cinderella of the cardiovascular risk profile. There are recent efforts to give renal dysfunction the status of a major cardiac risk factor, similar to diabetes mellitus, where Haffner and colleagues16 had shown that mortality in diabetics without a history of cardiac events was equal to that in nondiabetic patients surviving a myocardial infarction. As a result, in diabetic patients cardiovascular prophylaxis, including administration of ACE inhibitors (independent of blood pressure) and of statins (independent of low density lipoprotein cholesterol values) has been advocated. It will have to be seen whether renal dysfunction will be given a similar status. Nevertheless, in my opinion, because of the excessive cardiac risk, treating a patient with renal dysfunction should no longer be regarded as primary, but rather as secondary prevention. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. REFERENCES 1. Lindner A, Charra B, Sherrard DJ y cols.: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974. 2. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 160615, 1999. 3. Santopinto JJ, Fox KAA, Goldberg RJ y cols.: Creatinine clearance and adverse hospital outcomes in patients with acute 14. 15. 16. coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 89: 1003-8, 2003. Shlipak MG, Heidenreich PA, Noguchi H y cols.: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-62, 2002. Wright RS, Reeder GS, Herzog CA y cols.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137: 563-70, 2002. Henry RM, Kostense PJ, Bos G y cols.: Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 62: 1402-7, 2002. Muntner P, He J, Hamm L y cols.: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-53, 2002. Ruilope LM, Salvetti A, Jamerson K y cols.: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12: 218-25, 2001. Mann JF, Gerstein HC, Pogue J y cols.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-36, 2001. Hillege HL, Girbes AR, de Kam PJ y cols.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-10, 2000. Kielstein JT, Boger RH, Bode-Boger SM y cols.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-6, 2002. Stefanski A, Schmidt KG, Waldherr R y cols.: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50: 1321-6, 1996. Fliser D, Pacini G, Engelleiter R y cols.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343-7, 1998. Chen J, Muntner P, Hamm LL y cols.: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469-77, 2003. Klein IH, Ligtenberg G, Oey PL y cols.: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-33, 2001. Haffner SM, Lehto S, Ronnemaa T y cols.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-34, 1998. 72 "
    "pdfFichero" => "P7-E232-S132-A2999.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029465/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029465/v0_201502091335/en/P7-E232-S132-A2999.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029465?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 3 6 9
2024 Octubre 31 34 65
2024 Septiembre 34 27 61
2024 Agosto 42 44 86
2024 Julio 28 20 48
2024 Junio 53 35 88
2024 Mayo 42 28 70
2024 Abril 34 36 70
2024 Marzo 31 21 52
2024 Febrero 28 41 69
2024 Enero 30 22 52
2023 Diciembre 26 21 47
2023 Noviembre 25 23 48
2023 Octubre 23 30 53
2023 Septiembre 22 26 48
2023 Agosto 28 26 54
2023 Julio 28 28 56
2023 Junio 75 23 98
2023 Mayo 59 32 91
2023 Abril 37 18 55
2023 Marzo 25 15 40
2023 Febrero 23 22 45
2023 Enero 24 24 48
2022 Diciembre 39 28 67
2022 Noviembre 38 23 61
2022 Octubre 28 49 77
2022 Septiembre 32 29 61
2022 Agosto 49 34 83
2022 Julio 24 44 68
2022 Junio 26 37 63
2022 Mayo 31 38 69
2022 Abril 32 48 80
2022 Marzo 32 32 64
2022 Febrero 30 34 64
2022 Enero 29 31 60
2021 Diciembre 32 36 68
2021 Noviembre 26 33 59
2021 Octubre 25 31 56
2021 Septiembre 26 34 60
2021 Agosto 21 31 52
2021 Julio 33 24 57
2021 Junio 22 15 37
2021 Mayo 19 27 46
2021 Abril 55 51 106
2021 Marzo 29 25 54
2021 Febrero 30 15 45
2021 Enero 15 13 28
2020 Diciembre 16 13 29
2020 Noviembre 21 6 27
2020 Octubre 21 13 34
2020 Septiembre 11 6 17
2020 Agosto 21 9 30
2020 Julio 32 9 41
2020 Junio 21 13 34
2020 Mayo 21 17 38
2020 Abril 33 18 51
2020 Marzo 22 9 31
2020 Febrero 31 18 49
2020 Enero 33 23 56
2019 Diciembre 26 14 40
2019 Noviembre 33 16 49
2019 Octubre 13 11 24
2019 Septiembre 12 12 24
2019 Agosto 6 9 15
2019 Julio 23 25 48
2019 Junio 18 12 30
2019 Mayo 12 24 36
2019 Abril 45 28 73
2019 Marzo 19 19 38
2019 Febrero 15 10 25
2019 Enero 19 20 39
2018 Diciembre 37 26 63
2018 Noviembre 66 10 76
2018 Octubre 61 14 75
2018 Septiembre 34 10 44
2018 Agosto 16 11 27
2018 Julio 33 8 41
2018 Junio 17 7 24
2018 Mayo 21 10 31
2018 Abril 24 10 34
2018 Marzo 22 4 26
2018 Febrero 16 6 22
2018 Enero 20 2 22
2017 Diciembre 20 5 25
2017 Noviembre 19 4 23
2017 Octubre 19 3 22
2017 Septiembre 10 8 18
2017 Agosto 14 4 18
2017 Julio 9 5 14
2017 Junio 10 4 14
2017 Mayo 11 4 15
2017 Abril 21 8 29
2017 Marzo 9 9 18
2017 Febrero 13 2 15
2017 Enero 5 5 10
2016 Diciembre 29 2 31
2016 Noviembre 34 3 37
2016 Octubre 36 4 40
2016 Septiembre 63 5 68
2016 Agosto 108 1 109
2016 Julio 105 0 105
2016 Junio 50 0 50
2016 Mayo 80 0 80
2016 Abril 24 0 24
2016 Marzo 34 0 34
2016 Febrero 47 0 47
2016 Enero 44 0 44
2015 Diciembre 64 0 64
2015 Noviembre 51 0 51
2015 Octubre 48 0 48
2015 Septiembre 37 0 37
2015 Agosto 38 0 38
2015 Julio 23 0 23
2015 Junio 14 0 14
2015 Mayo 20 0 20
2015 Abril 7 0 7
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología